Qorvo's Closing Spread Is Not a Long Opportunity

Summary: Qorvo's last regular-session close, $114.17 on Oct. 2, was already essentially equal to the $114.1288 consideration implied by Skyworks' $32.50 cash plus 0.960 SWKS shares, marked to SWKS's $85.03 close. Skyworks said all required regulatory clearances were received and the parties expected to close on or about Oct. 5, subject to remaining customary conditions. That changes the old regulatory-spread thesis into a near-term completion/break event, but does not create a long edge: the modeled base is flat, the credible break stress is materially worse than 5%, and the shares are expected to be halted/suspended around closing. Reject / no-trade screen.

Opportunity Ranking

Rank	Candidate	Direction	Mispricing	Evidence Freshness	Catalyst Window	Positioning	10/5 Status	Tradeability	Main Rejection Risk
1	Qorvo (QRVO)	Long	Oct. 2 close is $0.041 above deal value marked to SWKS close; almost no remaining spread	Sep. 30 Skyworks clearance release, SEC exhibit and Nasdaq corporate-action notice; Oct. 2 closes	Expected merger close on or about Oct. 5	Merger-arbitrage ownership/flows are unknown; price is pinned near consideration	Reject: base -0.04%; break stress -19.3%	Last expected trading date was Oct. 2; close is near-immediate and stock may be halted	Failed/ delayed closing or a SWKS move changes consideration; cash/stock value is not fixed
2	Novo Nordisk (NVO)	Long	Denecimig's review delay is explicitly manufacturing-related, with no clinical deficiency and no 2026 outlook impact; product-level sales bridge remains undisclosed	Oct. 2 issuer update	FDA remediation and eventual U.S. decision; no new action date	Current product/option positioning not verified	Reject / insufficient long edge	Oct. 2 close $37.32 is a reference only; no valuation bridge ties denecimig to a 10% base	Manufacturing delay can persist or worsen; a clinical distinction does not establish near-term revenue
3	StoneX (SNEX)	Long	Colombian coffee acquisition is described as immediately accretive, but consideration, target earnings, and purchase terms are not disclosed in the release	Oct. 2 issuer announcement	Closing of definitive-agreement acquisition; timing and conditions not stated in release	Current positioning not verified	Reject / insufficient long edge	Oct. 2 close $65.81 is a reference only; no per-share contribution can be modeled	Unknown price, integration economics, coffee exposure and target cash flow
Control	SPDR S&P 500 ETF (SPY)	Long	Broad-market reference, not an issuer-specific mispricing	Oct. 2 close	No single near-term catalyst selected	Broad market positioning not assessed	No selected 10/5 setup	Oct. 2 close $769.64; no live execution evidence	Index-level macro and concentration risk

Selected opportunity: QRVO, as the highest-information-value rejection, not as the best executable opportunity.

Why this one now: The evidence boundary materially changed since the Desk's May 8 Qorvo article, which analyzed a regulatory spread after shareholder approval. On Sep. 30, Skyworks reported receipt of all necessary regulatory clearances and expected closing on or about Oct. 5; Nasdaq then identified Oct. 2 as the anticipated last trading date and published the stock/ cash terms. This is a distinct closing-state test, not a refreshed version of the earlier regulatory thesis.

What should surprise the reader: The consideration is variable because most of it is SWKS stock. At the Oct. 2 regular closes, QRVO traded about four cents above the implied consideration, not at a material discount. A successful deal therefore does not imply meaningful positive QRVO return from that reference; a deal break is not protected by the conditional reverse termination fee.

Why This Is the Best Opportunity Right Now

QRVO ranks first for decision value because both the exchange notice and the consideration formula make the long payoff unusually auditable over a short, dated window. The arithmetic rejects the trade quickly. NVO is a genuine fresh regulatory/operating development, but management says the delay does not change its 2026 outlook and has not disclosed the product's revenue contribution. SNEX's claimed accretion cannot be tested without price and earnings inputs. None supplies a better underwritten long.

The ranking is not a claim that QRVO offers superior expected return. It is a choice of the most falsifiable candidate among the screened names. SPY is included as a broad-market control rather than a fourth issuer thesis.

Why This Can Move More Than 5% Soon

The merger is binary over a short period. A successful close converts QRVO shares into $32.50 cash plus 0.960 SWKS shares, subject to the transaction terms; a failure or material delay can remove the deal value and return the stock to standalone trading. A historical pre-announcement reference is $92.13, QRVO's Oct. 27, 2025 close immediately before the announcement. That is a break stress, not current standalone fair value or a floor. A move from $114.17 to $92.13 is -19.3%.

The completed Oct. 2 regular close is the model basis. StockAnalysis reports QRVO at $114.17, up 1.75%, on 7.396 million shares; Skyworks' investor historical lookup reports SWKS at $85.03, up 2.25%, on 8.734 million shares. SPY closed at $769.64, up 0.74%. Price/volume do not establish arbitrage fund positioning. Current holders, short interest, hedges, borrow, and forced flows are unknown.

The same secondary QRVO history page shows an after-hours reference of $114.65 at 7:34 p.m. EDT on Oct. 2. Nasdaq's notice anticipated a halt around 7:50 p.m. and identified Oct. 2 as the last trading date. The after-hours mark is not used in the model; no synchronized SWKS after-hours quote or executable book was verified. It cannot be treated as a new entry.

10/5 Asymmetry Gate

Test	Result
Reference basis	QRVO $114.17 Oct. 2 regular close; not an entry
Highest-probability base	$114.1288 from $32.50 + 0.960 × SWKS $85.03; -0.04% gross
Credible adverse case	$92.13 historical unaffected-close stress; -19.3%; not a floor or current valuation
Gross base/adverse ratio	0:1 for decision purposes; base return is slightly negative
Probability-weighted value	$113.54 using 5% / 92% / 3% judgmental weights; -0.55% before costs
Costs and path	Spread/slippage, custody/settlement, and any residual execution friction only worsen a near-zero gross edge; deal may close while QRVO is halted
Status	Reject / no trade

The 10/5 hurdle fails before costs: base is not +10%, adverse stress exceeds -5%, and gross reward/risk is below 2:1. The probability estimates below are low-confidence analyst judgments, not observed frequencies. Even a successful close is not a catalyst for a 10% gain from the Oct. 2 reference unless SWKS rises substantially before the merger exchange value is fixed; that would be SWKS exposure, not a QRVO-specific mispricing.

What Should Surprise the Reader

The reverse termination fee is not a $100 million per-shareholder floor. The merger agreement makes it payable only under specified regulatory/foreign-investment termination circumstances. It is a corporate payment to Qorvo in those defined states, not a guarantee that QRVO stock holders recover the deal price or avoid a gap. The source agreement also says Skyworks financing is not a condition to its obligation to close, reducing one financing contingency but not removing the remaining closing conditions.

The separate Qorvo note exchange offers do not condition the merger closing. Skyworks' Oct. 2 SEC-filed release says those offers are conditioned on the merger, not vice versa, and would be extended beyond closing. Note exchange results therefore should not be mistaken for a remaining merger vote or a per-share consideration adjustment.

The Setup

Fact: The original signed consideration is $32.50 cash plus 0.960 SWKS shares per QRVO share. On Sep. 30, Skyworks said all necessary clearances had been received and the parties expected to close on or about Oct. 5, subject to satisfaction or waiver of remaining customary conditions. Nasdaq's corporate-action alert states that Qorvo shareholders approved the merger on Feb. 11 and gives the same consideration.

Inference: The market had largely capitalized the near-term close by Oct. 2. The near-zero difference between QRVO's close and the marked consideration is consistent with that reading, but the price alone cannot reveal a precise deal-completion probability because SWKS consideration moves with SWKS and the close occurs at a later mark.

Unknown: Whether every non-regulatory closing condition was satisfied or waived as of this publication time; the exact SWKS reference used for final settlement; synchronized after-hours value; arbitrage positioning; and realistic post-halt exit mechanics. Skyworks describes remaining customary conditions, not a completed transaction. This screen does not assume the merger already closed.

The Market Price

Observation	Price	Change / detail	Use
QRVO regular close, Oct. 2, 4:00 p.m. EDT	$114.17	+1.75%; 7,395,686 shares, StockAnalysis	Sole QRVO model reference
SWKS regular close, Oct. 2, 4:00 p.m. EDT	$85.03	+2.25%; 8,733,605 shares, Skyworks investor lookup	Marks the stock component only
Consideration marked to SWKS close	$114.1288	$32.50 + 0.960 × $85.03	Formula-derived reference, not cash proceeds yet
QRVO after-hours, Oct. 2, 7:34 p.m. EDT	$114.65	Secondary quote page; before anticipated ~7:50 p.m. halt	Context only; excluded from scenarios
SPY regular close, Oct. 2	$769.64	+0.74%	Broad-market comparison

The $0.0412 excess of QRVO's regular close over the marked consideration is about 0.04% of the share price. This is not an arbitrage return estimate after settlement timing, costs, or the final SWKS value. At the after-hours QRVO mark, the comparison to the regular-session SWKS mark would be asynchronous and is therefore not a valid spread calculation.

The Mispricing

The candidate mispricing is that the market might be underpricing the probability of prompt completion despite all required regulatory clearances and an announced Oct. 5 target. The contrary price evidence is decisive for a long: the $114.17 close is already at the $114.1288 consideration mark. The incremental convergence payoff is approximately zero, not 10%.

The strongest alternative interpretation is that an expected closing date can slip or fail, so the closing spread should remain positive. That is plausible and is exactly why the downside cannot be called bounded. But if the residual uncertainty is large enough to justify a meaningful discount, the long has a poor asymmetry: the successful case is near flat while a break can erase a large portion of the deal-related rerating.

The Positioning

No current holder, merger-arbitrage book, SWKS hedge ratio, borrow, short-interest, options, or dealer exposure data was verified. The Oct. 2 volumes and positive returns are observed market data, not direct positioning evidence. Calling the stock “crowded” or “short squeezed” would exceed the evidence.

The consideration itself gives a mechanical event map: QRVO holders receive a cash component and SWKS shares if the transaction closes. That does not make a QRVO common position a fixed-value cash claim before closing. The variable stock leg, final settlement reference, potential halt, and break risk remain relevant.

The Catalyst

Step	State and timing	Observable test	Failure / delay path
Shareholder approvals	QRVO approval recorded Feb. 11; Skyworks' Sep. 30 release says necessary clearances now received	Read issuer closing release and Nasdaq final corporate-action status	A representation, covenant, injunction, or other remaining condition prevents close
Expected transaction close	On or about Oct. 5, subject to remaining customary conditions	Form 8-K/issuer release confirms effective time and exchange mechanics	Delay, termination, or settlement issue; shares may be halted while uncertainty resolves
Qorvo trading suspension	Nasdaq anticipated Oct. 2 as last trading date and suspension effective Oct. 6 if close occurs	Nasdaq completion notice and successor/ticker treatment	No orderly exit at the reference price once halted or suspended
Qorvo note exchange	Offers expected to extend past close; merger not conditioned on exchange results	Skyworks files extension and settlement results	Debt exchange may vary without changing the basic merger condition

Cheapest falsification sequence: Check for a filed closing notice, Nasdaq corporate-action update, and any issuer notice that a remaining condition failed. Re-mark $32.50 + 0.960 × the contemporaneous SWKS value only if synchronized trading data exist. There is no reason to place or stage an order while QRVO is expected to be halted and a close is imminent.

The Payoff

The position is an unlevered common-stock long in QRVO for the analysis, but it is not recommended. The core consideration is partly floating: $32.50 cash plus 0.960 SWKS shares. A successful merger gives the holder successor shares, not a fixed cash amount. A failed deal returns the holder to standalone QRVO risk after a major event repricing.

The historical $92.13 Oct. 27, 2025 regular close is used only as a coarse break stress because it immediately preceded the public announcement. It is not a forecast, today's standalone estimate, a protected level, or an assertion that the business has not changed. A true standalone break valuation would require a refreshed Qorvo operating and valuation model, which is not decision-relevant for this near-immediate screen and is not claimed here.

Price Target and Probability Map

All cases use the QRVO Oct. 2 regular close of $114.17 and the same horizon: the expected transaction outcome by Oct. 5, 2026, or the next public resolution if the close is delayed. The top case marks the stock leg to SWKS's Oct. 2 intraday high as a reference sensitivity; it is not a claim that the merger price locks at that high. The bottom is the historical unaffected-close stress.

Scenario	Probability	Target / Level	Return / Payoff	Horizon	Conditions	Evidence Quality
Top Case	5%	$115.58	+1.23%	By Oct. 5 close / next resolution	Close occurs and SWKS consideration reference is near the Oct. 2 high of $86.54	Low; intraday mark, not settlement price
Base Case	92%	$114.13	-0.04%	By Oct. 5 close	Close occurs with SWKS near the Oct. 2 $85.03 close	Medium for consideration math; low for probability
Bottom Case	3%	$92.13	-19.30%	By Oct. 5 or next public resolution	Deal fails or materially breaks; price stress references the pre-announcement Oct. 27, 2025 close	Low; old unaffected mark is not current fair value
Invalidation	n/a	Close is confirmed and QRVO exchange terms settle	No continuing QRVO thesis; security is exchanged/delisted	At effective time	Filed completion and exchange state	High once filed

Probability-weighted expected value: $113.54, or -0.55% gross versus $114.17. The three scenario probabilities sum to 100%; the 5% / 92% / 3% weights are subjective, low-confidence estimates, not observed merger-arbitrage frequencies. No positive after-cost case is established.

Current market level and timestamp: QRVO $114.17 at Oct. 2, 2026, 4:00 p.m. EDT / 20:00 UTC; latest completed regular session at the actual Oct. 4 02:15 SGT publication time.

Primary instrument: QRVO common stock, evaluated but not recommended.

10/5 favorable base move: -0.04% gross.

10/5 credible adverse move: -19.30% historical break stress; not bounded.

10/5 measurement basis: reference-only; executable entry is null.

10/5 status: Reject / no trade.

Confidence: High that the arithmetic fails the long hurdle; low on event probabilities and standalone break value.

Sensitivity

At the Oct. 2 SWKS close, the deal consideration is $114.1288. Each $1 move in SWKS changes per-share QRVO consideration by $0.96, about 0.84% of the QRVO reference. The theoretical value reaches $125.5875 (+10% on $114.17) only if SWKS is about $96.97 at the valuation point, a roughly 14.0% rise from $85.03; that is a semiconductor-market exposure, not a demonstrated QRVO mispricing. A $1 rise in the probability assigned to the bottom case, funded from the base case, reduces weighted value by about $0.22 per QRVO share using this stress. The reference-only expected value is already negative before costs.

The Kill Shot

Strongest counterargument: A near-term close after all required regulatory clearances and two shareholder approvals makes break probability low; the $100 million reverse termination fee in specified regulatory cases and Skyworks' committed financing might appear to cushion failure. This case deserves serious weight: regulatory uncertainty has materially declined, and financing is not a closing condition.

Why it does not rescue the long: The reverse fee is contingent on specified termination states, belongs to Qorvo at the corporate level, and is not a per-share guarantee or price floor. Financing being non-conditional removes one dependency, not all representations, covenants, injunction, or material-adverse-effect conditions. Most importantly, a very high probability of a flat-value closing still does not satisfy a +10% base hurdle.

Load-bearing assumption: The deal closes on approximately the announced schedule and the Oct. 2 SWKS close is a useful proxy for the settlement stock value. If the close fails, the break stress may understate current standalone value; if SWKS rises sharply, the value delivered to Qorvo holders rises too, but investors could own SWKS directly rather than pay a merger uncertainty premium.

What Could Go Wrong

A remaining closing condition fails, a court or authority intervenes, a representation or covenant issue emerges, or the effective time slips. The shares could gap while halted, with no executable exit at the displayed reference.
SWKS moves between the last QRVO trading session and exchange settlement, changing the value of the stock leg. The Oct. 2 close is stale for execution and only a model anchor.
A matching after-hours SWKS quote was not verified, so the Oct. 2 QRVO after-hours observation cannot support a synchronized consideration comparison.
Historical standalone price is not a current value floor. If Qorvo fundamentals weakened since October 2025, a break could be worse; if they improved, the stress could exaggerate downside. Neither direction is quantified here.
The deal could close yet realized value differ through fractional-share cash treatment, withholding, settlement timing, and security conversion mechanics.
Thin residual spread is easily erased by spread, slippage, fees, taxes, and operational costs; halt and suspension make exit liquidity a discontinuous rather than continuous risk.

What Would Prove This Wrong

This screen's conclusion is about the long 10/5 hurdle, not whether the merger ultimately closes. A new, verified consideration adjustment, a material SWKS price increase before settlement, or a signed revised transaction could change the payoff map. It would not qualify a trade unless a fresh long has at least a +10% highest-probability base, no more than -5% credible adverse path, 2:1 gross reward/risk, positive value after costs, and complete execution evidence. A filed successful closing would instead end the QRVO thesis and make the common stock unavailable as a continuing instrument.

Risk Audit

Question	Assessment
Mature counterparty view	Clearances and approvals are complete; the announced close is days away; close probability is high
Most fragile assumption	Oct. 2 SWKS close approximates settlement value, while remaining closing conditions are routine
What market may already know	The price is already at the stock/cash consideration and Nasdaq published the expected last trade date
Directionally right but losing	Deal closes, but SWKS falls before settlement; or residual trading/settlement costs exceed the tiny spread
Gap / halt risk	High in event terms; Nasdaq anticipated a halt followed by suspension on close
Positioning evidence	Unknown; price and volume do not prove arb crowding
Execution state	Entry null; execution false; last expected trading date already passed
Protection	None that bounds common-stock downside; reverse fee is conditional corporate recovery, not a holder hedge

Best Trade Strategy

No trade. Do not buy QRVO to capture the merger consideration. The reference price leaves essentially no spread, does not provide a 10% base, and the security is at the end of its expected trading life. Do not use options, leverage, margin, a market order, or an assumed price floor. A direct SWKS position is a separate semiconductor investment thesis and is not proposed here.

Execution is blocked independently of the failed economics: no live spread, depth, venue, volume-quality, final-session execution quote, or exit-capacity evidence is available, and the exchange has announced the anticipated halt/suspension path. The only valid next action is to monitor the issuer closing filing and Nasdaq corporate-action completion notice; after closing, remove QRVO from the active opportunity set.

Sources

Skyworks SEC-filed release: all necessary regulatory clearances; expected close on or about Oct. 5; note exchange is not a merger condition, Sep. 30, 2026.
Nasdaq Equity Corporate Actions Alert #2026-702, Sep. 30, 2026: anticipated last trading date, halt/suspension, shareholder approval, and consideration.
Skyworks Form 8-K, Feb. 11 stockholder vote, approval of the Skyworks stock-issuance proposal.
Skyworks investor historical price lookup, SWKS Oct. 2 regular OHLCV.
Qorvo historical price page, QRVO Oct. 2 close, OHLCV, and separately timestamped after-hours mark. Secondary quote data; not executable.
Skyworks/Qorvo merger agreement filed with the SEC, Oct. 28, 2025: consideration, closing conditions, financing and conditional reverse termination fee.
Skyworks SEC filing on the merger agreement, Oct. 28, 2025: financing is not a condition to closing and merger termination mechanics.
Qorvo historical price page, Oct. 27, 2025 unaffected-close reference. Secondary historical price data.
Novo Nordisk Oct. 2 denecimig BLA update, primary issuer source for the NVO screen.
StoneX Oct. 2 Integra acquisition release, primary issuer source for the SNEX screen.
SPY Oct. 2 historical close, secondary market data for the broad-market control.
NVO Oct. 2 historical close, secondary market data for the NVO comparison.
SNEX Oct. 2 historical close and volume, secondary market data for the SNEX comparison.

Research Quality Scorecard

Criterion	Score	Evidence-based reason
Market disagreement	4/5	Consideration and last trade are directly comparable; the remaining disagreement is event risk versus near-zero spread
Evidence base	5/5	Fresh issuer, SEC, Nasdaq and dated close evidence; scenario probability remains subjective
Positioning and flows	2/5	Direct arb ownership, short interest and hedge data are unavailable
Catalyst path	5/5	Closing window and post-close trading path are exchange-noticed, though not completed
Payoff architecture	4/5	Cash/stock consideration is explicit; break price is only a historical stress, not a valuation
Invalidation discipline	5/5	Completion, delay, halt, and exchange states are observable and separately defined
Differentiated insight	4/5	Shows why a $100M reverse fee is not an equity floor and why the debt exchange is not a close condition
Client value	5/5	The arithmetic explains why a likely close still fails the long hurdle and identifies the final verification steps

Total: 34/40. Publishable as a no-trade screen, not as a trade-qualified idea. The score does not override the failed 10/5 gate.

Bottom Line

Regulatory risk has fallen; long-side payoff has not improved enough. At the Oct. 2 close, the consideration formula implied $114.1288 against a $114.17 QRVO print. The base case is effectively flat, while a deal break carries a plausible double-digit gap risk and the expected trading window is ending. QRVO is the most auditable rejection in this U.S. long screen, not an opportunity to buy.

AI Illustration Prompt

Create a restrained institutional editorial illustration for The Mispricing Desk: on a dark graphite trading desk, place a Qorvo share certificate beside a precise merger ledger showing “$32.50 CASH + 0.960 SWKS SHARES” and a small quote strip “QRVO $114.17 / IMPLIED $114.13.” A physical red halt marker interrupts the final line of an exchange calendar stamped “OCT 5 EXPECTED CLOSE,” while a steel balance scale shows a nearly level deal value against a much heavier conditional “BREAK RISK” folder. Include a small footnote plate “$100M REVERSE FEE: SPECIFIC CONDITIONS, NOT A SHAREHOLDER FLOOR.” Use paper white, graphite, subdued semiconductor blue, and a restrained amber event marker; no arrows implying a guaranteed payout, no generic candlestick chart, no corporate logos, no hype. Add a subtle readable “The Mispricing Desk” watermark etched along the lower-right edge.